|
|
|
| Study on the therapeutic effect of four antituberculous regimens combined with the drug Moxifloxacin on tuberculous pleurisy |
| JIA Wen-cheng1 LU Guan-nan2▲ |
1.The Five Treatment Areas of Tuberculosis,the Fourth Hospital of Chaoyang City,Liaoning Province,Chaoyang 122000,China;
2.Department of Respiratory Medicine,Affiliated Hospital of Jilin Medical University,Jilin Province,Jilin 132013,China |
|
|
|
|
Abstract Objective To explore the therapeutic effect of the quadruple anti-tuberculosis program combined with the drug Moxifloxacin on tuberculous pleurisy.Methods A total of 48 cases of tuberculous pleurisy patients admitted to the Fourth Hospital of Chaoyang City from April 2017 to April 2018 were selected as the research objects,and were divided into the control group(24 cases)and the experimental group(24 cases)according to the random number table method.The control group was treated with a quadruple anti-tuberculosis regimen combined with conventional treatment,and the experimental group was treated with a quadruple anti-tuberculosis regimen combined with the drug Moxifloxacin.The immune function indicators of the two groups were compared,including the levels of T lymphocyte subsets CD8+,CD4+,CD4+/CD8+,and the levels of serum inflammatory factors including interferon-α(INF-α),interferon-γ(INF-γ),and interleukin 2(IL-2),interleukin 4(IL-4),interleukin 10(IL-10),clinical efficacy.Results The CD8+,CD4+,CD4+/CD8+,INF-γ,INF-α of the experimental group after treatment were higher than those of the control group,and the differences were statistically significant(P＜0.05).The IL-2,IL-4,IL-10 of the experimental group after treatment were lower than the control group,the differences were statistically significant(P<0.05).There were no significant difference in CD8+,CD4+,CD4+/CD8+,INF-γ,INF-α,IL-2,IL-4 and IL-10 between two groups before treatment(P>0.05).CD8+,CD4+,CD4+/CD8+,INF-γ,INF-α after treatment in the two groups were all higher than before treatment,and the differences were statistically significant(P<0.05).The IL-2,IL-4,and IL-10 levels of the two groups after treatment were lower than before treatment,and the differences were statistically significant(P<0.05).The total clinical effective rate(87.50%)of the experimental group was higher than that of the control group(54.16%),the difference was statistically significant(P<0.05).Conclusion The quadruple anti-tuberculosis regimen combined with the drug Moxifloxacin has a significant therapeutic effect in patients with tuberculous pleurisy,which can effectively inhibit the development of the disease and reduce adverse reactions.It is worthy of promotion and application.
|
|
|
|
|
|
| [1] |
厉娟，罗丹霖，张勇.胸腔闭式引流联合莫西沙星对结核性胸膜炎患者血清和胸腔积液炎性相关细胞因子的影响[J].湖南师范大学学报（医学版），2019，16（6）：37-41.
|
| [2] |
金武，宋斌，卢水华，等.莫西沙星联合四联抗结核方案治疗结核性胸膜炎临床研究[J].中华医院感染学杂志，2019，29（14）：2090-2094.
|
| [3] |
罗伟桃.胸腔内注射尿激酶、异烟肼和地塞米松治疗结核性胸膜炎的疗效观察[J].临床医药文献电子杂志，2019，6（38）：165-166.
|
| [4] |
唐怡敏.胸腔积液IGRA 联合生物标记物优化结核性和恶性胸膜炎鉴别诊断[D].衡阳：南华大学，2019.
|
| [5] |
王震，牛腾腾，赵含信，孙传忠，郭锋.结核感染T 细胞斑点试验联合腺苷脱氨酶在结核性胸膜炎中的诊断价值[J].实用医学杂志，2019，35（7）：1154-1158.
|
| [6] |
吴艳玲.异烟肼联合地塞米松胸腔注射治疗结核性胸膜炎的临床效果观察[J].北方药学，2019，16（4）：118-119.
|
| [7] |
陶冠宇，杨仁旭，任焱，等.卷曲霉素联合莫西沙星胸腔注射对结核性胸膜炎患者血清和胸腔积液IFN-γTNFαCEA ADA 水平的影响[J].河北医学，2018，24（6）：898-902.
|
| [8] |
邢小明.莫西沙星早期强化治疗结核性胸膜炎的临床效果及用药安全性[J].临床医学研究与实践，2018，3（16）：16-18.
|
| [9] |
黄娟，雍小兰，陈章，等.莫西沙星在结核性胸膜炎患者体内的药动学及胸膜透过性[J].中国新药与临床杂志，2017，36（4）：234-238.
|
| [10] |
阚宗卫.莫西沙星联合尿激酶治疗包裹性结核性胸膜炎胸膜增厚疗效分析[J].中外医疗，2017，36（1）：131-133.
|
| [11] |
陆阿楠.抗结核药物联合胸腺肽对老年结核性胸膜炎的疗效观察[J].中国医学工程，2018，26（9）：55-57.
|
| [12] |
孙海柏，张丽霞，刘佳庆，等.XpertMTB/RIF 联合T-SPOT.TB 对结核性胸膜炎及其耐药性的临床研究[J].中国现代医学杂志，2018，28（11）：99-103.
|
| [13] |
李磊.胸腔置管联合抗结核药治疗结核性胸膜炎患者胸腔积液的疗效分析[J].国际外科学杂志，2018，45（1）：25-28.
|
| [14] |
徐齐峰，宋晓东，张娜.胸腺肽联用抗结核药物对结核性胸膜炎患者炎性因子水平的影响[J].中国实用医药，2018，13（30）：12-14.
|
| [15] |
朱凤娟.增加胸穿抽液次数联合尿激酶治疗结核性胸膜炎的效果分析[J].中国药物经济学，2019，14（3）：85-88.
|
| [16] |
姜振东，王晓云，岳阳.左氧氟沙星和莫西沙星治疗耐多药肺结核临床效果对比分析[J].中国医药科学，2019，（9）：77-79.
|
|
|
|
